1-3 of 3
Deanna Brackman
Close
Sort by
Journal Articles

A First-in-Human Phase 1 Study of Abbv-319, an Antibody-Drug Conjugate Composed of a CD19 Antibody Linked to a Potent Proprietary Glucocorticoid Receptor Modulator, in Patients with Relapsed or Refractory B-Cell Malignancies

Moshe Levy, Carl Gustafson, James Purcell, Kevin J. Freise, Wissam Assaily, Deanna Brackman, William R. Henner, Michael McDevitt, John Kuruvilla
Journal: Blood
Blood (2022) 140 (Supplement 1): 3746–3747.
https://doi.org/10.1182/blood-2022-166809
Published: 2022
Journal Articles

Venetoclax Exposure-Efficacy and Exposure-Safety Relationships in Subjects with Treatment-Naïve Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

Doerthe Eckert, MSc, Deanna Brackman, PhD, Rajeev Menon, PhD, Ahmed Hamed Salem, PhD FCP, Jalaja Potluri, MD, B. Douglas Smith, MD, Andrew H. Wei, John Hayslip, MD MSCR, Dale Miles, PhD, Sven Mensing, PhD, Sathej Gopalakrishnan, PhD, Jiuhong Zha, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 52.
https://doi.org/10.1182/blood-2020-136425
Published: 2020
Journal Articles

Two Phase 1b Studies Evaluating the Safety and Tolerability of BET Inhibitors, ABBV-744 and Mivebresib, as Monotherapies and in Combination with Ruxolitinib or Navitoclax in Patients with Myelofibrosis

John Mascarenhas, MD, Rabih Saab, PhD, Deanna Brackman, PhD, Dimple A. Modi, PhD, Linu Abraham, PhD, James E. Ward, MD, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-137686
Published: 2020